October 27, 2020 -- Sensorion and Novasep have signed an agreement for the manufacturing of adeno-associated virus (AAV) vectors covering a gene therapy program that targets OTOF, the gene encoding the otoferlin protein. Mutations of OTOF can lead to severe congenital hearing loss.
OTOF-GT, Sensorion's most advanced program, aims to restore the expression of otoferlin in the inner hair cells of the ear, where it plays an essential role in hearing.
Under the terms of the agreement, Novasep will be in charge of developing and manufacturing the two AAV vectors designed for Sensorion's OTOF-GT product and will supply drug product batches to support preclinical and clinical studies. Development and manufacturing activities include cell culture, AAV expression, purification, aseptic distribution, and quality control.